Xencor (XNCR) Stock: Charts & Financials

Xencor, Inc.(XNCR)

Biotechnology · Pasadena, CA

$24.36-1.27 (-4.96%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Xencor, Inc.

Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.

Pasadena, CA

260 employees

www.xencor.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bassil I. Dahiyat

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	104.97M	51.22M	4.52M	28.24M	21.00M	43.61M	32.73M	70.02M	17.80M
Cost of Goods Sold	59.51M	0.00	2.57M	2.58M	54.37M	2.65M	2.69M	0.00	58.23M
Gross Profit	45.46M	51.22M	1.95M	25.66M	-33.37M	40.95M	30.04M	70.02M	-40.43M
Gross Profit Margin	43.3%	100.0%	43.2%	90.9%	-158.9%	93.9%	91.8%	100.0%	-227.2%
Total Operating Expenses	261.54M	88.29M	79.81M	79.29M	14.15M	74.13M	73.22M	65.97M	14.77M
Research & Development	255.76M	71.91M	64.67M	64.82M	54.37M	61.66M	58.58M	51.06M	58.23M
Selling, General & Administrative	65.28M	16.38M	17.71M	17.04M	14.15M	15.12M	17.34M	14.91M	14.77M
Operating Income (EBIT)	-216.08M	-37.07M	-77.86M	-53.63M	-47.52M	-33.17M	-43.18M	4.05M	-55.20M
Operating Margin	-205.8%	-72.4%	-1724.1%	-189.9%	-226.3%	-76.1%	-131.9%	5.8%	-310.2%
Income Before Tax (EBT)	-160.85M	-21.92M	-128.64M	-4.27M	-6.03M	-31.07M	-48.27M	-52.63M	-47.44M
Interest Income	23.00M	4.80M	5.46M	6.20M	6.54M	7.25M	7.54M	8.16M	7.54M
Interest Expense	27.07M	7.35M	4.70M	7.35M	7.67M	8.24M	8.66M	33.93M	795K
Other Income/Expense	55.23M	15.15M	-50.77M	49.36M	41.49M	2.10M	-5.08M	-56.67M	7.75M
Net Income	-163.32M	-21.73M	-128.92M	-6.65M	-6.03M	-30.82M	-48.42M	-53.48M	-46.29M
Income Tax Expense	2.48M	-190K	280K	2.39M	0.00	-250K	367K	1.50M	0.00
Net Profit Margin	-155.6%	-42.4%	-2854.7%	-23.6%	-28.7%	-70.7%	-147.9%	-76.4%	-260.1%
EBITDA	-205.90M	-34.63M	-75.30M	-51.05M	-44.93M	-30.52M	-40.49M	7.04M	-52.14M
EBITDA Margin	-196.1%	-67.6%	-1667.3%	-180.8%	-214.0%	-70.0%	-123.7%	10.1%	-293.0%
Depreciation & Amortization	10.17M	2.44M	2.57M	2.58M	2.59M	2.65M	2.69M	2.99M	3.05M
EPS Basic	-2.17	-0.29	-1.71	-0.09	-0.08	-0.41	-0.66	-0.73	-0.71
EPS Diluted	-2.17	-0.29	-1.71	-0.09	-0.08	-0.41	-0.66	-0.73	-0.71
Weighted Average Basic Shares	75.86M	75.86M	75.25M	74.24M	74.41M	74.28M	73.67M	73.18M	64.02M
Weighted Average Diluted Shares	75.86M	75.86M	75.25M	74.24M	74.41M	74.28M	73.67M	73.18M	64.02M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

104.97M

51.22M

4.52M

28.24M

21.00M

43.61M

32.73M

70.02M

17.80M

Cost of Goods Sold

59.51M

0.00

2.57M

2.58M

54.37M

2.65M

2.69M

0.00

58.23M

Gross Profit

45.46M

51.22M

1.95M

25.66M

-33.37M

40.95M

30.04M

70.02M

-40.43M

Gross Profit Margin

43.3%

100.0%

43.2%

90.9%

-158.9%

93.9%

91.8%

100.0%

-227.2%

Total Operating Expenses

261.54M

88.29M

79.81M

79.29M

14.15M

74.13M

73.22M

65.97M

14.77M

Research & Development

255.76M

71.91M

64.67M

64.82M

54.37M

61.66M

58.58M

51.06M

58.23M

Selling, General & Administrative

65.28M

16.38M

17.71M

17.04M

14.15M

15.12M

17.34M

14.91M

14.77M

Operating Income (EBIT)

-216.08M

-37.07M

-77.86M

-53.63M

-47.52M

-33.17M

-43.18M

4.05M

-55.20M

Operating Margin

-205.8%

-72.4%

-1724.1%

-189.9%

-226.3%

-76.1%

-131.9%

5.8%

-310.2%

Income Before Tax (EBT)

-160.85M

-21.92M

-128.64M

-4.27M

-6.03M

-31.07M

-48.27M

-52.63M

-47.44M

Interest Income

23.00M

4.80M

5.46M

6.20M

6.54M

7.25M

7.54M

8.16M

7.54M

Interest Expense

27.07M

7.35M

4.70M

7.35M

7.67M

8.24M

8.66M

33.93M

795K

Other Income/Expense

55.23M

15.15M

-50.77M

49.36M

41.49M

2.10M

-5.08M

-56.67M

7.75M

Net Income

-163.32M

-21.73M

-128.92M

-6.65M

-6.03M

-30.82M

-48.42M

-53.48M

-46.29M

Income Tax Expense

2.48M

-190K

280K

2.39M

0.00

-250K

367K

1.50M

0.00

Net Profit Margin

-155.6%

-42.4%

-2854.7%

-23.6%

-28.7%

-70.7%

-147.9%

-76.4%

-260.1%

EBITDA

-205.90M

-34.63M

-75.30M

-51.05M

-44.93M

-30.52M

-40.49M

7.04M

-52.14M

EBITDA Margin

-196.1%

-67.6%

-1667.3%

-180.8%

-214.0%

-70.0%

-123.7%

10.1%

-293.0%

Depreciation & Amortization

10.17M

2.44M

2.57M

2.58M

2.59M

2.65M

2.69M

2.99M

3.05M

EPS Basic

-2.17

-0.29

-1.71

-0.09

-0.08

-0.41

-0.66

-0.73

-0.71

EPS Diluted

-2.17

-0.29

-1.71

-0.09

-0.08

-0.41

-0.66

-0.73

-0.71

Weighted Average Basic Shares

75.86M

75.25M

74.24M

74.41M

74.28M

73.67M

73.18M

64.02M

Weighted Average Diluted Shares

75.86M

75.25M

74.24M

74.41M

74.28M

73.67M

73.18M

64.02M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	125.58M	110.49M	174.62M	164.58M	275.11M	122.69M	156.70M	40.60M
Cost of Goods Sold	10.51M	227.69M	0.00	199.56M	192.51M	169.80M	118.59M	97.50M
Gross Profit	115.06M	-117.19M	174.62M	-34.98M	82.60M	-47.11M	38.11M	-56.90M
Gross Profit Margin	91.6%	-106.1%	100.0%	-21.3%	30.0%	-38.4%	24.3%	-140.1%
Total Operating Expenses	292.57M	61.22M	306.98M	47.49M	38.84M	29.69M	24.29M	119.97M
Research & Development	239.43M	227.69M	253.60M	199.56M	192.51M	169.80M	118.59M	97.50M
Selling, General & Administrative	63.64M	58.89M	53.38M	47.49M	38.84M	29.69M	24.29M	22.47M
Operating Income (EBIT)	-177.50M	-178.41M	-132.36M	-82.47M	43.77M	-76.80M	13.82M	-79.37M
Operating Margin	-141.4%	-161.5%	-75.8%	-50.1%	15.9%	-62.6%	8.8%	-195.5%
Income Before Tax (EBT)	-89.42M	-234.92M	-119.63M	-54.51M	82.63M	-69.33M	27.19M	-70.41M
Interest Income	27.52M	31.93M	18.63M	4.82M	862K	7.26M	13.62M	9.10M
Interest Expense	31.93M	36.64M	N/A	N/A	13K	N/A	N/A	16K
Other Income/Expense	87.87M	-56.52M	12.73M	27.96M	38.86M	7.46M	13.36M	8.96M
Net Income	-91.92M	-232.62M	-133.13M	-55.18M	82.63M	-69.33M	26.88M	-70.41M
Income Tax Expense	2.50M	1.62M	13.66M	673K	0.00	0.00	312K	0.00
Net Profit Margin	-73.2%	-210.5%	-76.2%	-33.5%	30.0%	-56.5%	17.2%	-173.4%
EBITDA	-166.99M	-166.30M	-120.86M	-73.67M	51.26M	-71.00M	18.12M	-76.12M
EBITDA Margin	-133.0%	-150.5%	-69.2%	-44.8%	18.6%	-57.9%	11.6%	-187.5%
Depreciation & Amortization	10.51M	12.11M	11.50M	8.80M	7.49M	5.79M	4.30M	3.25M
EPS Basic	-1.24	-3.58	-2.08	-0.93	1.42	-1.11	0.48	-1.31
EPS Diluted	-1.24	-3.58	-2.08	-0.93	1.37	-1.11	0.46	-1.31
Weighted Average Basic Shares	74.24M	65.04M	60.50M	59.65M	58.38M	57.21M	56.53M	53.75M
Weighted Average Diluted Shares	74.24M	65.04M	60.50M	59.65M	60.50M	57.21M	58.47M	53.94M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

125.58M

110.49M

174.62M

164.58M

275.11M

122.69M

156.70M

40.60M

Cost of Goods Sold

10.51M

227.69M

0.00

199.56M

192.51M

169.80M

118.59M

97.50M

Gross Profit

115.06M

-117.19M

174.62M

-34.98M

82.60M

-47.11M

38.11M

-56.90M

Gross Profit Margin

91.6%

-106.1%

100.0%

-21.3%

30.0%

-38.4%

24.3%

-140.1%

Total Operating Expenses

292.57M

61.22M

306.98M

47.49M

38.84M

29.69M

24.29M

119.97M

Research & Development

239.43M

227.69M

253.60M

199.56M

192.51M

169.80M

118.59M

97.50M

Selling, General & Administrative

63.64M

58.89M

53.38M

47.49M

38.84M

29.69M

24.29M

22.47M

Operating Income (EBIT)

-177.50M

-178.41M

-132.36M

-82.47M

43.77M

-76.80M

13.82M

-79.37M

Operating Margin

-141.4%

-161.5%

-75.8%

-50.1%

15.9%

-62.6%

8.8%

-195.5%

Income Before Tax (EBT)

-89.42M

-234.92M

-119.63M

-54.51M

82.63M

-69.33M

27.19M

-70.41M

Interest Income

27.52M

31.93M

18.63M

4.82M

862K

7.26M

13.62M

9.10M

Interest Expense

31.93M

36.64M

N/A

13K

N/A

16K

Other Income/Expense

87.87M

-56.52M

12.73M

27.96M

38.86M

7.46M

13.36M

8.96M

Net Income

-91.92M

-232.62M

-133.13M

-55.18M

82.63M

-69.33M

26.88M

-70.41M

Income Tax Expense

2.50M

1.62M

13.66M

673K

0.00

312K

0.00

Net Profit Margin

-73.2%

-210.5%

-76.2%

-33.5%

30.0%

-56.5%

17.2%

-173.4%

EBITDA

-166.99M

-166.30M

-120.86M

-73.67M

51.26M

-71.00M

18.12M

-76.12M

EBITDA Margin

-133.0%

-150.5%

-69.2%

-44.8%

18.6%

-57.9%

11.6%

-187.5%

Depreciation & Amortization

10.51M

12.11M

11.50M

8.80M

7.49M

5.79M

4.30M

3.25M

EPS Basic

-1.24

-3.58

-2.08

-0.93

1.42

-1.11

0.48

-1.31

EPS Diluted

-1.24

-3.58

-2.08

-0.93

1.37

-1.11

0.46

-1.31

Weighted Average Basic Shares

74.24M

65.04M

60.50M

59.65M

58.38M

57.21M

56.53M

53.75M

Weighted Average Diluted Shares

74.24M

65.04M

60.50M

59.65M

60.50M

57.21M

58.47M

53.94M

Income Statement

Quarterly Income Statement (USD)

Annual Income Statement (USD)